J Breast Cancer.  2011 Feb;14(Suppl 1):S31-S36. 10.4048/jbc.2011.14.S.S31.

Serum Level Change of Follicle Stimulating Hormone in Menopausal Women with Breast Cancer according to Age in Korea

• Yi O
• Son BH
• Lee JW
• Kim HJ
• Ko BS
• Yu JH
• Lee YM
• Kwon SB
• Shin EJ
• Ahn SH

• KMID: 1340911
• DOI: http://doi.org/10.4048/jbc.2011.14.S.S31

Abstract

PURPOSE
The aim of this study is to evaluate the relationship of menopause and serum follicle stimulating hormone (FSH) level and estradiol (E2) in Korean women with breast cancer.
METHODS
We reviewed 1,404 women aged from 20- to 82-year-old (median 47 years) with breast cancer who had got surgery at Asan Medical Center in 2008. All patients were checked serum FSH before the operation. Three hundred fifty-three patients were in postmenopause state at the time of surgery. Their ages were from 40- to 60-year-old (median 50.3 years).
RESULTS
The proportion of postmenopausal status in each age-group were 5.1% (45- to 49-year-old), 41% (50- to 54-year-old), 86.1% (55- to 59-year-old), and 100% over the age of 60, respectively. And the proportion of the patients with FSH over 30 mUI/mL were 68.6% (45- to 49-year-old), 87.5% (55- to 59-year-old), 75.0% (55- to 59-year-old) and 30.0% (over the age of 60), respectively.
CONCLUSION
Our study shows that even though patients had been in amenorrhea over 1 year, not all patients have their FSH level over 30 mUI/mL. And this finding is more prominent in age group from 45- to 49-year-old.

Keyword

Breast neoplasms; Follicle stimulating hormone; Menopause

MeSH Terms

Female
Humans
Breast Neoplasms

Figure

• 

  Figure 1 Proportion of menopausal status. The histograms is displayed proportion of menopausal status according to age groups.

• 

  Figure 2 Proprotion of menopausal status according to age of 50-60. The histograms is subdivided 50th age group in Figure 1, and displayed proportion of menopausal status according to age.

• 

  Figure 3 Proportions of FSH ≥30 according to age group in postmenopausal patients. It is displayed proportion of FSH over 30 mIU/mL in patients who had been ammenorrhea over 1 yr. FSH=follicle stimulating hormone.

• 

  Figure 4 Proportions of E2 ≤20 according to age group in postmenopausal patients. It is displayed proportion of E2 less than 20 mIU/mL in patients who had been ammenorrhea over 1 yr. E2=estradiol.

• 

  Figure 5 Proprotion of FSH ≥30 and E2 ≥20 according to age group in postmenopausal patients. It is displayed proportion of FSH more 30 mIU/mL and E2 less than 20 mIU/mL patients who had been ammenorrhea over 1 yr. FSH=follicle stimulating hormone; E2=estradiol.

Reference

1. Suh CS. Review: endocrinology of perimenopause. J Korean Soc Menopause. 2003. 9:299–304.

2. Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P, et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature. 1986. 320:134–139.

3. Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J. Sequence and expression of human estrogen receptor complementary DNA. Science. 1986. 231:1150–1154.

4. Kim HJ, Nam-Gung JM, Koh JM, Lee JS, Hong SJ, Kwak BS, et al. Relationship of bone mineral density and the risk of breast cancer in Korean postmenopausal women. J Breast Cancer. 2006. 9:330–336.

5. Harris JR. Diseases of the Breast. 2010. 4th ed. Philadelphia: Lippincott Williams & Wilkins;616–617.

6. Miller WR. Bilological rationale for endocrine therapy in breast cancer. Best Pract Res Clin Endocrinol Metab. 2004. 18:1–32.

7. Ahn SH, Kim MK, Kim SI. Relation between body size and body mass index and breast cancer by menopausal status in Korea. J Korean Cancer Assoc. 1999. 31:72–81.

8. The Korean Breast Cancer Society. Nationwide Korean breast cancer data of 2004 using breast cancer registration program. J Breast Cancer. 2006. 9:151–161.

9. Surveilance report: public health weekly report 35. Korea Centers for Disease Control and Prevention. Accessed January 24th, 2010. http://www.cdc.go.kr/kcdchome/jsp/home/common/brd/COMMBRD1200Detail.jsp?boardid=1545&boardseq=33&menuid=&appid=null&contentid=null&pageNum=null&tabinx=null&pageNo=6&q_value=&q_name=&sub=null.

10. Burger HG, Dudley EC, Robertson DM, Dennerstein L. Hormonal changes in the menopause transition. Recent Prog Horm Res. 2002. 57:257–275.

11. Hale GE, Burger HG. Hormonal changes and biomarkers in late reproductive age, menopausal transition and menopause. Best Pract Res Clin Obstet Gynaecol. 2009. 23:7–23.

12. Gracia CR, Sammel MD, Freeman EW, Lin H, Langan E, Kapoor S, et al. Defining menopause status: creation of a new definition to identify the early changes of the menopausal transition. Menopause. 2005. 12:128–135.

13. Gill S, Lavoie HB, Bo-Abbas Y, Hall JE. Negative feedback effects of gonadal steroids are preserved with aging in postmenopausal women. J Clin Endocrinol Metab. 2002. 87:2297–2302.

14. Kim YK, Lee JY, Oh ST, Park YS, Kang SW. The efficacy of measuring intercycle variablility of FSH, LH, FSH and LH ratios and E2 predicting ovarian reserve in normal women age 40-45 years. J Korean Soc Menopause. 1998. 4:219–227.

15. Studd JW, Chakravarti S, Collins WP. Plasma hormone profiles after the menopause and bilateral oöphorectomy. Postgrad Med J. 1978. 54:Suppl 2. 25–30.

16. Coble YD, Kohler PO, Cargille CM, Ross GT. Production rates and metabolic clearance rates of human follicle-stimulating hormone in premenopausal and postmenopausal women. J Clin Invest. 1969. 48:359–363.

17. Chakravarti S, Collins WP, Forecast JD, Newton JR, Oram DH, Studd JW. Hormonal profiles after the menopause. Br Med J. 1976. 2:784–787.

18. Kwekkeboom DJ, de Jong FH, van Hemert AM, Vandenbroucke JP, Valkenburg HA, Lamberts SW. Serum gonadotropins and alpha-subunit decline in aging normal postmenopausal women. J Clin Endocrinol Metab. 1990. 70:944–950.

19. Prescription drugs are administered to cancer patients, information about the revised announcement 2009-3. Health Insurance Review & Assessment Service. Accessed November 8th, 2010. http://www.hira.or.kr/common/dummy.jsp?pgmid=HIRAA030103000000.